Sickle Cell Disease News

First SCD patient enrolled in Phase 1b trial of oral therapy iadademstat

The first sickle cell disease patient has been enrolled in a Phase 1b trial testing iadademstat, Oryzon Genomics' ...
Sickle Cell Disease News

Trial of Pociredir for SCD completes enrollment of high-dose group

A Phase 1b clinical trial testing pociredir in adults with sickle cell disease has completed enrollment of its high-dose ...

Beam Therapeutics: SCD Catalysts Have Untapped Upside Potential

Beam Therapeutics Inc. trades at a relatively cheap valuation based on its multiples and potential in SCD. Learn more about ...

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...
GEN

Sanofi, Scribe Launch Up-to-$1.2B Collaboration in SCD, Genomic Diseases

Scribe Therapeutics Co-Founder, President and CEO Benjamin L. Oakes, PhD A growing landscape for sickle cell disease (SCD) treatments, a growing relationship between the companies, and the potential ...
The American Journal of Managed Care

Fertility Risks and Treatments Misunderstood by Patients With SCD

Results from a cross-sectional study revealed the gaps in knowledge related to fertility risks among patients with sickle cell disease (SCD), as well as shed light on patient perspectives on fertility ...